The AUCs obtained from the ROC analysis of PFN1 slightly decreased in patients with AAA of the validation study, whereas those of CFD in the validation study increased to 0.802 and 0.847 in patients with TAA and AAA, respectively, when compared with the discovery study. This evidence concerns the gene PFN1 and triple-A syndrome.